LEADER 01077nam0-2200337---450- 001 990009539980403321 005 20120307135230.0 010 $a88-14-14944-5 020 $aIT$b2009-413 035 $a000953998 035 $aFED01000953998 035 $a(Aleph)000953998FED01 035 $a000953998 100 $a20120307d2009----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ay-------001yy 200 1 $a<>danno non patrimoniale$eguida commentata alle decisioni delle S. U., 11 novembre 2008, nn. 26972/3/4/5$fC. Amato ... [et al.] 210 $aMilano$cGiuffrè$dc2009 215 $aXII, 566 p.$d24 cm. 517 1 $a<>danno non patrimoniale$eguida commentata alle decisioni delle Sezioni Unite, 11 novembre 2008, nn. 26972/3/4/5 610 0 $aDanni morali$aLegislazione 676 $a346.450 33$v21 702 1$aAmato,$bCristina 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990009539980403321 952 $a19 B 401$b15047$fDDCP 959 $aDDCP 996 $aDanno non patrimoniale$9229504 997 $aUNINA LEADER 01361nam--2200433---450- 001 990000878210203316 005 20050426104411.0 035 $a0087821 035 $aUSA010087821 035 $a(ALEPH)000087821USA01 035 $a0087821 100 $a20020116h----1981km-y0itay0103----ba 101 $aita 102 $aIT 105 $a||||||||001yy 200 1 $a<> alfabeto delle stelle$fMarco Ramperti$gcon una nota di Leonardo Sciascia 210 $aPalermo$cSellerio$h1981 215 $a212 p$cill., fotogr.$d17 cm 225 2 $aLa memoria$v37 410 $12001$aLa memoria$v37 606 0 $aArtiste di cinematografo$xSaggi 676 $a791.430280922 700 1$aRAMPERTI,$bMarco$0207358 702 1$aSCIASCIA,$bLeonardo 801 0$aIT$bsalbc$gISBD 912 $a990000878210203316 951 $aXIII.2. 46a(XVI D 44)$b138898 LM$cXVI D 951 $aXVI D 44 BIS$b133327 LM$cXVI D 951 $aXIII.2. 46(Varie Coll. 420/37)$b133327 L.M.$cVarie Coll. 959 $aBK 969 $aUMA 979 $aPATTY$b90$c20020116$lUSA01$h1318 979 $c20020403$lUSA01$h1732 979 $aPATTY$b90$c20020408$lUSA01$h1537 979 $aPATRY$b90$c20040406$lUSA01$h1700 979 $aCOPAT3$b90$c20050126$lUSA01$h1354 979 $aCOPAT1$b90$c20050426$lUSA01$h1044 996 $aAlfabeto delle stelle$9969910 997 $aUNISA LEADER 04810nam 2200661 a 450 001 9910806999703321 005 20200520144314.0 010 $a9786613203854 010 $a9781283203852 010 $a1283203855 010 $a9781118075678 010 $a1118075676 010 $a9781118075685 010 $a1118075684 010 $a9781118075661 010 $a1118075668 035 $a(CKB)2550000000041471 035 $a(EBL)697533 035 $a(OCoLC)828303987 035 $a(SSID)ssj0000535802 035 $a(PQKBManifestationID)12200792 035 $a(PQKBTitleCode)TC0000535802 035 $a(PQKBWorkID)10546284 035 $a(PQKB)11038768 035 $a(MiAaPQ)EBC697533 035 $a(PPN)240475747 035 $a(Perlego)1011792 035 $a(EXLCZ)992550000000041471 100 $a20110121d2011 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDetection and quantification of antibodies to biopharmaceuticals $epractical and applied considerations /$fedited by Michael G. Tovey 205 $a1st ed. 210 $aHoboken, N.J. $cWiley$dc2011 215 $a1 online resource (442 p.) 300 $aDescription based upon print version of record. 311 08$a9780470566664 311 08$a0470566663 320 $aIncludes bibliographical references and index. 327 $aPrincipals of risk assessment and monitoring of antibody responses to biopharmaceuticals / Eugen Koren, Erik Foehr, and Charles A. O'Neill -- Immunogenicity of therapeutic proteins : a regulatory perspective / Susan Kirshner -- Guidance on immunogenicity assessment of biologically-derived therapeutic proteins : an European perspective / Meenu Wadhwa and Robin Thorpe -- Japanese regulatory perspective on immunogenicity / Takao Hayakawa and Akiko Ishii -- Enzyme immunoassays and radioimmune assays for quantification of anti-TNF biopharmaceuticals and anti-drug antibodies / Klaus Bendtzen and Morten Svenson -- Confirmatory immunogenicity assays / Eric Wakshull and Daniel Coleman -- The use of pharmacodynamics as a surrogate marker for the detection of anti-drug neutralizing antibodies / Florian Deisenhammer -- Cell-based assays for the detection of neutralizing antibodies to interferon beta (IFN-?) and tumor necrosis factor-alpha (TNF-?) inhibitors / Anthony Meager -- Detection of neutralizing antibodies (NABs) to Interferon-beta by real time RT-PCR / Francesca Gilli and Antonio Bertolotto -- Competitive ligand binding assays for the detection of neutralizing antibodies / Bonnie Wu, George R. Gunn III, and Gopi Shankar -- 327 $aThe use of surface plasmon resonance for the detection and characterization of antibodies / Steven J. Swanson and Daniel Mytych -- Hypersensitivity reactions to biopharmaceuticals : detection and quantification of drug-specific IgE antibodies / Jrgen Dahlstrm and Lennart Venemalm -- Standardization and validation of immunoassays and biophysical assays for the detection of anti-drug antibodies / Daniel Kramer -- Standardization and validation of cell-based assays for the detection of neutralizing anti-drug antibodies / Deborah Finco-Kent and Amy Grenham -- Standardization of neutralizing antibody unitge by bioassay design : constant antigen and constant antibody methodology / Sidney E. Grossberg, Yoshimi Kawade, and Leslie D. Grossberg -- Cut-points and performance characteristics for anti-drug antibody assays / Viswanath Devanarayan and Michael G. Tovey -- Dilutional linearity for neutralizing antibody assays / David Lansky and Carrie Wager -- Detection of neutralizing antibodies to biopharmaceuticals in the presence of high levels of circulating drug / Arno Kromminga and Michael G. Tovey. 330 $a The definitive book on the neutralization of recombinant biopharmaceuticals Recombinant biopharmaceuticals are an important tool for treating a range of illnesses; however, their efficacy can be severely impaired by their immunogenicity. When introduced into the body, these pharmaceuticals can cause the immune system to produce anti-drug antibodies (ADAs) that neutralize their effects. The first and only book to cover neutralization in connection with biopharmaceuticals and the measurement and application of neutralizing antibodies in modern medicine at any real length, Detection an 606 $aImmunoglobulins$xAnalysis 606 $aImmunoassay 615 0$aImmunoglobulins$xAnalysis. 615 0$aImmunoassay. 676 $a616.07/98 701 $aTovey$b Michael G$01698469 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910806999703321 996 $aDetection and quantification of antibodies to biopharmaceuticals$94079969 997 $aUNINA